Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ProQR Therapeutics N.V. PRQR

Healthcare  —  Biotechnology
1.65 (0.06) (3.51%) as of 25 Sep
Market cap
$236.1M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

ProQR Therapeutics N.V. (PRQR) Business Profile

Updated before January 2025

Company Overview

ProQR Therapeutics N.V. (PRQR) is a biotechnology company dedicated to developing transformative RNA therapies for genetic disorders. Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR has established itself as a pioneer in the field of RNA-based therapeutics. The company was co-founded by Daniel de Boer, who also serves as the Chief Executive Officer (CEO). Under his leadership, ProQR has focused on leveraging RNA technology to address unmet medical needs, particularly in the area of rare genetic diseases. The company’s leadership team includes experienced professionals from the biotechnology and pharmaceutical industries, ensuring a strong foundation for innovation and growth.

ProQR is publicly traded on the NASDAQ stock exchange under the ticker symbol PRQR. Since its inception, the company has been committed to advancing science and improving the lives of patients with genetic disorders, particularly those affecting the eyes and other tissues.

Core Business Segments

ProQR Therapeutics focuses on developing RNA-based therapies for rare genetic disorders. The company’s core business segments include:

1. Ophthalmology

ProQR’s primary focus is on developing therapies for inherited retinal diseases (IRDs), which are a group of rare genetic disorders that lead to vision loss. Key products and programs under this segment include:

  • Sepofarsen (QR-110): A lead investigational therapy for Leber congenital amaurosis 10 (LCA10), a severe genetic eye disorder caused by mutations in the CEP290 gene. Sepofarsen is designed to restore vision by targeting the underlying genetic defect.
  • QR-421a: A therapy in development for Usher syndrome type 2A, a condition that causes combined hearing and vision loss. QR-421a targets mutations in the USH2A gene.
  • QR-1123: A program targeting autosomal dominant retinitis pigmentosa (adRP), a progressive eye disease caused by mutations in the RHO gene.

2. RNA Platform Technology

ProQR has developed a proprietary RNA platform technology that enables the design and development of RNA-based therapies. This platform is the foundation for the company’s pipeline of innovative treatments and allows for the rapid development of therapies targeting a wide range of genetic disorders.

Business Model

ProQR’s business model is centered around the development and commercialization of RNA-based therapies. The company generates revenue through:

  1. Research and Development Collaborations: ProQR partners with other biotechnology and pharmaceutical companies to co-develop therapies and share expertise. These collaborations often include milestone payments and royalties on future product sales.
  2. Licensing Agreements: The company licenses its RNA platform technology and specific therapeutic programs to other organizations, generating upfront payments and ongoing royalties.
  3. Grants and Funding: ProQR receives funding from government agencies, non-profit organizations, and other entities to support its research and development efforts.

ProQR’s approach integrates cutting-edge RNA technology with a patient-centric focus, ensuring that its therapies address the underlying causes of genetic disorders and improve patient outcomes.

Strategic Direction

ProQR is committed to advancing its pipeline of RNA-based therapies and expanding its reach in the field of genetic medicine. Key strategic priorities include:

  1. Pipeline Expansion: ProQR aims to broaden its portfolio of RNA therapies by targeting additional genetic disorders beyond ophthalmology. The company is exploring opportunities in other therapeutic areas, such as neurology and dermatology.
  2. Global Market Access: ProQR is focused on securing regulatory approvals and expanding access to its therapies in key markets, including the United States, Europe, and Asia.
  3. Sustainability Goals: The company is dedicated to sustainable practices in its operations and research activities, ensuring long-term value creation for stakeholders.
  4. Partnerships and Collaborations: ProQR continues to seek strategic partnerships with academic institutions, research organizations, and industry leaders to accelerate the development and commercialization of its therapies.

Competitive Landscape

ProQR operates in a highly competitive biotechnology sector, where it faces competition from companies developing therapies for genetic disorders. Key competitors include:

  • Ionis Pharmaceuticals: A leader in RNA-targeted therapeutics with a broad pipeline of antisense oligonucleotide therapies.
  • Editas Medicine: A company focused on gene editing technologies, including CRISPR-based therapies for genetic eye disorders.
  • Sarepta Therapeutics: Known for its RNA-based therapies targeting rare genetic diseases, particularly in neuromuscular disorders.
  • Wave Life Sciences: A biotechnology company developing stereopure oligonucleotide therapies for genetic diseases.

ProQR differentiates itself through its proprietary RNA platform technology and focus on rare genetic eye disorders, which represent significant unmet medical needs.

Risk Factors

ProQR faces several risks that could impact its business operations and financial performance, including:

  1. Regulatory Challenges: The development and approval of RNA-based therapies are subject to stringent regulatory requirements, which can delay or prevent product commercialization.
  2. Market Dependence: ProQR’s success depends on the commercial viability of its lead programs, such as sepofarsen. Failure to achieve market acceptance could adversely affect the company’s revenue.
  3. Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers for the production of its therapies. Any disruptions in the supply chain could impact product availability.
  4. Competition: The biotechnology sector is highly competitive, and ProQR faces challenges from established players and emerging startups.
  5. Financial Risks: As a clinical-stage company, ProQR relies on external funding to support its operations. Limited financial resources could hinder its ability to advance its pipeline.

Recent Developments

ProQR has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trials: The company has reported positive interim results from clinical trials of sepofarsen for LCA10, demonstrating its potential to restore vision in patients with this rare genetic disorder.
  • Partnerships: ProQR has entered into strategic collaborations with leading biotechnology companies to co-develop RNA therapies and expand its reach in the genetic medicine space.
  • Corporate Initiatives: The company has implemented cost-saving measures and streamlined its operations to focus on its core therapeutic areas.

Global developments, such as the COVID-19 pandemic, have posed challenges to clinical trial timelines and supply chain operations. However, ProQR has adapted to these challenges by leveraging digital technologies and maintaining close communication with stakeholders.

Investment Considerations

Investors considering ProQR as a potential investment should weigh the following strengths and risks:

Strengths:

  • Innovative RNA Platform: ProQR’s proprietary RNA technology positions it as a leader in the field of genetic medicine.
  • Focused Pipeline: The company’s emphasis on rare genetic eye disorders addresses significant unmet medical needs.
  • Experienced Leadership: ProQR’s management team brings extensive expertise in biotechnology and drug development.

Risks:

  • Clinical and Regulatory Uncertainty: The success of ProQR’s therapies depends on positive clinical trial outcomes and regulatory approvals.
  • Financial Dependence: As a clinical-stage company, ProQR relies on external funding to support its operations.
  • Market Competition: The biotechnology sector is highly competitive, with numerous players developing RNA-based therapies.

Conclusion

ProQR Therapeutics N.V. is a pioneering biotechnology company focused on developing RNA-based therapies for rare genetic disorders. With a robust pipeline, innovative technology platform, and experienced leadership, ProQR is well-positioned to address significant unmet medical needs in the field of genetic medicine. While the company faces challenges related to regulatory approvals, market competition, and financial resources, its strategic direction and commitment to innovation provide a strong foundation for future growth. As ProQR continues to advance its pipeline and expand its global reach, it remains a compelling player in the biotechnology sector.